Legato Capital Management LLC Has $1.09 Million Stock Holdings in NovoCure Limited (NASDAQ:NVCR)

Legato Capital Management LLC decreased its position in NovoCure Limited (NASDAQ:NVCR) by 34.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 36,460 shares of the medical equipment provider’s stock after selling 19,107 shares during the period. Legato Capital Management LLC’s holdings in NovoCure were worth $1,087,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Choreo LLC bought a new stake in shares of NovoCure in the fourth quarter worth $251,000. China Universal Asset Management Co. Ltd. increased its stake in NovoCure by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,943 shares of the medical equipment provider’s stock valued at $684,000 after buying an additional 2,129 shares during the last quarter. KBC Group NV increased its stake in NovoCure by 65.1% in the 4th quarter. KBC Group NV now owns 5,091 shares of the medical equipment provider’s stock valued at $152,000 after buying an additional 2,008 shares during the last quarter. Blue Trust Inc. lifted its position in NovoCure by 70.7% during the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 781 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of NovoCure by 57.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider’s stock worth $129,000 after buying an additional 1,575 shares during the last quarter. Institutional investors and hedge funds own 84.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NVCR. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of NovoCure in a research report on Tuesday, January 14th. Evercore ISI upgraded NovoCure from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $18.00 to $30.00 in a research note on Monday, December 2nd. Piper Sandler raised their target price on shares of NovoCure from $28.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Finally, Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of NovoCure in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, NovoCure currently has an average rating of “Moderate Buy” and an average price target of $32.67.

NovoCure Price Performance

Shares of NovoCure stock opened at $21.37 on Thursday. The firm’s 50 day moving average is $27.88 and its 200 day moving average is $21.34. NovoCure Limited has a 1 year low of $11.70 and a 1 year high of $34.13. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27.

NovoCure Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.